Neoplasia/BPH

	Neoadjuvant and Adjuvant Therapies for High-Risk Prostate Cancer. Urol Clin North Am Penukonda S, Hyams E, Pareek G, Santopietro A, Carneiro B. PMID: 41986019 [PubMed - indexed for MEDLINE]
	Treatments on the Horizon for Men with Advanced Prostate Cancer. Urol Clin North Am Ehrlich MI, Gejman RS, Bernstein E, Stein MN. PMID: 41986027 [PubMed - indexed for MEDLINE]
	Systemic Treatments of Castration-Resistant Prostate Cancer. Urol Clin North Am Desai AN, Fleyshman M, Lall N, Saraiya B. PMID: 41986026 [PubMed - indexed for MEDLINE]
	Recent Advances in Understanding the Biology of Castration-Resistant Prostate Cancer. Urol Clin North Am Lluís D, Cheng W, Piulats JM, Heras L, Aytes Á, Kruithof de Julio M. PMID: 41986025 [PubMed - indexed for MEDLINE]
	Radiotherapy in Men with De Novo Metastatic Prostate Cancer. Urol Clin North Am Messing I, Rao YJ, Goyal S. PMID: 41986024 [PubMed - indexed for MEDLINE]
	Cytoreductive Radical Prostatectomy in Men with De Novo Metastatic Prostate Cancer. Urol Clin North Am Ragam R, Chua KJ, Wei J, Aron M. PMID: 41986023 [PubMed - indexed for MEDLINE]
	Systemic Treatments in Men with De Novo Metastatic Prostate Cancer. Urol Clin North Am Lim DH, Zhang A, Kim IY. PMID: 41986022 [PubMed - indexed for MEDLINE]
	Managing Prostate Cancer Biochemical Recurrence after Definitive Local Therapy. Urol Clin North Am Winograd J, Suzman E, Wang S, Hu JC. PMID: 41986021 [PubMed - indexed for MEDLINE]
	Managing Clinical N1 Prostate Cancer. Urol Clin North Am Imam S, Yuh B. PMID: 41986020 [PubMed - indexed for MEDLINE]
	Modern Radiotherapy for High-Risk and Very-High-Risk Prostate Adenocarcinoma. Urol Clin North Am Shen J, An Y. PMID: 41986018 [PubMed - indexed for MEDLINE]
	Role of Pelvic Lymph Node Dissection for Clinically Localized Prostate Cancer: Should It be Done? Urol Clin North Am Elkun Y, Gupta R, De Almeida Luz M, Tewari AK. PMID: 41986017 [PubMed - indexed for MEDLINE]
	Surgical Management of High-Risk Prostate Cancer. Urol Clin North Am Cheaib JG, Allaf ME. PMID: 41986016 [PubMed - indexed for MEDLINE]
	Re-Evaluating the Role of Locoregional Therapy in Metastatic Prostate Cancer: A Review of Current Evidence and Evolving Clinical Approaches. Urol Clin North Am Ajjawi I, Sprenkle PC, Renzulli JF, Leapman MS. PMID: 41986015 [PubMed - indexed for MEDLINE]
	High Risk Prostate Cancer: What is it? Urol Clin North Am Fu MZ, Golombos D, Ghodoussipour S. PMID: 41986014 [PubMed - indexed for MEDLINE]
	Comparative Performance of Prostate Cancer Risk Prediction Tools in Gay, Bisexual, and Other Men Who Have Sex with Men Versus Heterosexual Men. Urology Fink KE, Liu Y, Wiarda G, Gowda A, Chan D, Neill C, Silberman P, Amarasekera C, Patel HD, Ross AE, Sun Z, Murphy AB. PMID: 41985632 [PubMed - as supplied by publisher]
	The SUMMIT Study: A real-world, clinical study to evaluate the performance of the OptilumeÂ® BPH Catheter System in men with symptomatic Benign Prostatic Hyperplasia (BPH). Urology Siqueira MHB, Buksh O, Hammoud A, Bhojani N, Meskawi M, Chughtai B, Zorn KC, Lajkosz K, Zakaria A, Elmansy H, Patel P, Matsumoto E, Elterman D. PMID: 41985628 [PubMed - as supplied by publisher]
	Identification of MYC co-expression gene: POLR3G is associated with cell senescence, immunotherapy, chemotherapy responses, and clinical prognosis in bladder cancer patients. Transl Oncol Zhu L, Liu Y, Lan J, Cai E, Sun D, Liu J, Zong L, Cong Z. PMID: 41985320 [PubMed - as supplied by publisher]
	Mapping Radiotherapy Resources for Prostate Cancer Trials in Nigeria: A STAMPEDE 2-Site Survey. JCO Glob Oncol Fatiregun O, Lasebikan N, Ekeke O, Malami A, Gombe A, Sowunmi A, Olatunji-Agunbiade T, Balogun B, Borisade B, Sunday A, Tannock I, James N. PMID: 41985120 [PubMed - indexed for MEDLINE]
	Evaluating the correlation between biopsy frequency and reduced sexual function in prostate cancer patients under active surveillance: a prospective cohort study. J Sex Med Angulo-Llanos L, Cortizas EM, Williams AD, Howell NB, Guerard T, Punnen S, Masterson TA, Kava B. PMID: 41985042 [PubMed - indexed for MEDLINE]
	Clinical and Molecular Validation of the Very Favorable IMDC Risk Group in Metastatic Renal Cell Carcinoma. JAMA Netw Open Zarba M, Saad E, Semaan K, El Zarif T, Ferrier E, Wells C, El Hajj Chehade R, Basappa NS, Ebrahimi H, Huseni M, Banchereau R, McKay RR, Wood L, Beuselinck B, Suárez C, Takemura K, Lalani AA, Li H, Spain LA, Templeton AJ, Powles TB, Bjarnason GA, de Velasco G, Choueiri TK, Heng DYC. PMID: 41984479 [PubMed - indexed for MEDLINE]

Articles 1 - 20 / 187090

Page 1 of 9355



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy